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Summary Small intestine mucin antigen (SIMA) is an oncofoetal antigen for the colon and is distinct from
the normal large intestinal mucin antigen (LIMA). In the present study, a panel of anti-SIMA and anti-LIMA
monoclonal antibodies (MAb) was used to characterise altered mucin expression in colorectal adenocar-
cinomas, by immunohistochemistry and quantitative immunoassays of tissue extracts. These results are
compared with CEA expression and correlated with various clinicopathological indices. All mucin MAb
reacted with a high proportion of the 100 colon cancers of every stage, histological type (including non-
mucinous cancers), differentiation, site, or size. Inappropriate SIMA production was detected by either
anti-SIMA MAb 4D3 or 4AI, even in 85% ofearly stage cancers. MAb 4D3 reacted with a higher proportion
of cancers of smaller size and better differentiation. At the subcellular level, both anti-SIMA MAb showed
reactivity typical of normal mucin, i.e., goblet cell and extracellular mucin. The normal colonic antigen,
LIMA, was also detectable in the majority of cases, but quantitatively overproduced in some cases and
reduced in others. However, in contrast to SIMA, LIMA was detected in predominantly undifferentiated
cancer cells but not in goblet cells. Heterogeneity of MAb reactivity between cases and complementarity within
each cancer was frequently observed. Mucin reactive with at least one of the MAb was detected in all of the
CEA-negative cancers. A high rate of inappropriate SIMA expression was also detected in the perineoplastic
transitional mucosa (88%, c.f. CEA, 35%) and adjacent, morphologically normal mucosa (80% c.f. CEA,
24%), indicating biochemical changes similar to the cancer. This panel of anti-mucin MAb demonstrated
altered mucin glycoprotein metabolism associated with the development and progression of most colorectal
cancers, which emphasises their utility as indicators of neoplastic change in the colon, and their superiority to
CEA.
The mucin glycoproteins of the gastrointestinal tract are
extensively glycosylated, high molecular weight, multi-unit
structures which, in the normal epithelium, are secreted by
specialised goblet cells, and form a protective gel over the
underlying epithelium (Allen, 1983). Mucin glycoproteins
have also been demonstrated to be differentiation-associated
or oncofetal antigens in the gastrointestinal tract (Gold &
Miller, 1978; Ma et al., 1980; Bara et al., 1980; Hertzog et
al., 1991). Similar abnormalities of mucin glycoprotein ex-
pression have also been identified in other epithelial tissues,
including the breast (Griffiths et al., 1987) and ovary (Bhat-
tacharya et al., 1982). As with other oncofoetal antigens,
such as cell surface glycoproteins and glycolipids (Hakomori
& Kannagi, 1983; Feizi & Childs, 1985), mucin glycoproteins
may prove to be useful markers of neoplastic change and
their expression may be related to the growth characteristics
of a tumour, its invasiveness, its metastatic potential, or the
host response to the tumour (Pihl, 1984).
In view of the complex structure of mucins, a panel of
MAb with different specificities would be ideal reagents for
the detection of changes in composition of mucins that occur
under an oncogenic stimulus. We have described the produc-
tion of two MAb to intestinal cancer mucins and the pre-
liminary chemical characterisation of the mucin antigens
(Hertzog et al., 1991). One MAb designated anti-LIMA 2C3
reacted in the normal adult specifically with mucin of the
large intestine, yet showed oncofoetal reactivity with the
gastric epithelium. In contrast, another MAb designated anti-
SIMA 4D3 reacted in the normal adult specifically with
mucin of the small intestine, but showed oncofoetal reactivity
with both gastric and colorectal epithelium.
The purpose of this study was to use an expanded panel of
MAb to SIMA and LIMA to define the characteristics of
tumour-associated mucin expression in 100 cases of colorec-
tal cancer. In particular, we have assessed the amount of
mucin by semiquantitative immunohistochemistry and by
sandwich ELISA, and correlated the resulting data with
various clinicopathological indices and with expression of
CEA.
Materials and methods
Mucin extraction andfractionation
Mucins were extracted from specimens of resected cancers or
normal gastrointestinal tract using 4 M guanidine hydrochlor-
ide in phosphate buffered saline (PBS), containing the
protease inhibitors: 10 mm N-ethyl maleimide, 1 mM benzam-
idine hydrochloride, and 25 mM EDTA (Hertzog et al.,
1991). Homogenates were centrifuged at 20,000 x g for
20min, and the supernatants subjected to three cycles of
CsCl density gradient centrifugation for purification of mucin
fractions. SIMA banded at a mean buoyant density of
1.34 gml-' (range 1.32 to 1.37 gml-'), whereas LIMA ban-
ded at a mean buoyant density of 1.45 g ml-' (range
1.36-1.59 gml ') (Hertzog et al., 1991). Each fraction was
assayed for protein content (Bradford, 1976) and antigenicity
using sandwich ELISA as outlined below.
Preparation ofmonoclonal antibodies
The production of the anti-SIMA MAb 4D3 and the anti-
LIMA 2C3, using as immunogen, a mucin extract from an
adenocarcinoma of the colon (designated sample 1946), has
been described elsewhere (Hertzog et al., 1991). Additional
MAb were prepared similarly, but using as immunogen a
mucin extract from a different adenocarcinoma of the colon
(designated sample 3266). An indirect ELISA was used to
screen mouse serum samples or hybridoma culture super-
natants for mucin-specific antibodies as previously described
(Hertzog et al., 1991). In these assays, microtiter plates were
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coated with the immunogen, cancer mucin preparation 3266.
Hybridomas secreting antibodies reactive with mucin were
cloned at least twice by limiting dilution. MAb were charac-
terised by indirect and sandwich ELISA, and by immunohis-
tochemistry, according to their reactivity with mucin in the
normal gastrointestinal tract and in colorectal cancers.
Tissue samples
(i) Normal tissues Normal tissue specimens were obtained
by biopsy or at autopsy (5 to 7 h post mortem) from
subjects with no apparent gastrointestinal tract disease.
Samples were from stomach (15 cases: eight biopsy and
seven autopsy), small intestine (16 cases: nine biopsy,
seven autopsy), and large intestine (21 cases: 14 biopsy,
seven autopsy). A sample of each autopsy specimen was
fixed in 10% Formalin for immunohistochemical studies
and the remainder (up to 30 cm in length) was initially
frozen on dry ice, then stored at - 80°C, prior to
extraction of mucins.
(ii) Colorectal cancer tissues Formalin-fixed tissue speci-
mens were obtained from 100 colorectal cancers: 88
from surgical resection, and 12 by colonoscopic biopsy.
Six fresh specimens of colorectal cancers were obtained
within 2 h of surgical resection, initially frozen on dry
ice, then stored at - 80°C prior to extraction of mucins
as described above.
Case details
Cases included 53 females (mean age at time of resection of
70 years, s.e.m. 2.2 years, range 45-98 years) and 45 males
(mean age 66, s.e.m. 1.5 years, range 45-98). Of the 75 cases
where precise anatomical site of the cancer was specified,
24% were from the right colon, 24% from the left colon and
52% from the rectum. The remaining 25 cases were from
unspecified sites in the colon. There were 81 cases for which
clinicopathological staging according to the Dukes
classification was available: ofthese, 16% were Stage A, 30%
Stage B, 45% Stage C, and 9% Stage D.
Histopathology
Tissue samples were fixed in 10% neutral buffered formalin,
embedded in paraffin by means of a Histokinette Tissue
Processor (Hendry Relays Ltd., Slough, Buckinghamshire,
England), and serial 5 micron sections cut and mounted on
glass slides. In 50% of cases, multiple blocks (2 to 4) were
obtained. Assessments for mucin content and a number
of morphological parameters of grading and differentiation
were made on sections stained with Alcian Blue (pH 2.5)/
periodic acid-Schiff/Mayer's Haematoxylin, and recorded in
detail according to the criteria of Jass et al., 1986. The
parameters assessed were predominant tumour type (papil-
lary, tubular or mucinous), tubule configuration (complex,
simple, irregular or no tubules), nuclear polarity (easily
discerned, just discerned or lost), growth pattern at the
tumour margin (expanding or infiltrating), lymphocytic infil-
trate (marked, little or moderate) and fibrosis (little, mod-
erate or extensive).
Semiquantitative immunohistochemistry
Serial 5 micron sections were dewaxed and stained with
mouse anti-mucin MAb and rabbit anti-CEA antiserum
(Dakopatts, Denmark) by the indirect immunoperoxidase
technique, and counterstained with Mayer's Haematoxylin,
as described previously (Hertzog et al., 1991). Each immuno-
peroxidase experiment included normal adult small intestine
(positive control for anti-SIMA MAb, negative control for
anti-LIMA MAb), and normal adult large intestine (positive
control for anti-LIMA MAb, negative control for anti-SIMA
MAb). Additional negative controls included an anti-inter-
feron alpha mouse MAb IgG, or no MAb. At regular inter-
vals, the first and second antibodies were titrated to maintain
consistency of staining intensity.
The immunoperoxidase-stained slides were then viewed
under a Nikon light microscope, and assessed under code, by
two observers. Scores of 0-3 were assigned to intensity of
reactivity (weak, 1; moderate, 2; strong, 3) and distribution
(restricted, <25% positive, 1; patchy, 25-75%, 2; and
diffuse, >75%, 3) for each of the antibodies, in serial sec-
tions of cancer specimens. These scores were added to give a
single aggregate score from 0-6 for the reactivity of each
MAb in each section. Trace reactivity scored a maximum
aggregate of 1. As differentiation was noted to vary in
different blocks from the same case, each block was scored
separately for subsequent analysis. A total of 198 blocks
from 100 cases (50 cases with multiple blocks) was analysed.
A mean MAb reactivity score for each case was obtained for
each of the following four zones, where present: the cancer;
the transitional mucosa, two distinct zones of which have
been described, the narrow zone immediately adjoining the
cancer, which contains few goblet cells and many columnar
cells, and the broad zone beyond this, which shows hyper-
plasia of goblet cells and tall, dilated, irregularly-branched
crypts (Filipe, 1969), which we have designated, respectively,
the transitional mucosa I and II (TM-I and TM-II); and the
morphologically normal mucosa adjacent to this region.
Quantitation ofmucins by sandwich ELISA
Sandwich ELISA were developed to quantitate the immuno-
reactivity of mucin preparations from normal colon and
colonic cancer specimens. An assay was developed for each
of 4D3, 2C3, IOB3, 9B5, and 4A1, wherein the same MAb
was used as the capture antibody coated to the wells of
microtiter plates, and as the detecting antibody coupled to
alkaline phosphatase as described in detail previously for 2C3
and 4D3 (Hertzog et al., 1991). All MAb were purified using
Protein A sepharose affinity chromatography, prior to use in
sandwich ELISA. A description of the reference antigen stan-
dard (designated 1946) for the 2C3 and 4D3 assays has been
outlined elsewhere (Hertzog et al., 1991). Another mucin
preparation (designated 3266), which reacted strongly with
each of the new MAb, was selected as a reference standard
for these assays and was assigned an arbitrary value ex-
pressed as 'antibody-reactive units' per ml. Mucin antigen-
icity expresed in MAb-reactivity units per ml, as determined
by sandwich ELISA, represents a composite of antigen con-
centration, epitope density and MAb avidity. Consequently,
results from an assay with one MAb would not necessarily be
comparable with those using another MAb, particularly as
the frequency of any two epitopes on the complex antigen
may be different.
Results
Characteristics ofthe new MAb
Three MAb, designated 9B5, IOB3 and 4A1, were detected to
be reactive with the cancer mucin immunogen by indirect
screening ELISA. These were shown by indirect ELISA to be
reactive with SIMA and/or LIMA (data not shown). Thus,
MAb 4A1, reacted predominantly with SIMA. MAb 9B5
reacted predominantly with LIMA, whereas MAb IOB3
reacted equally well with LIMA and SIMA. These initial
results were confirmed by quantitative sandwich ELISA and
by immunohistochemistry (see below). The isotypes were:
9B5, IgG3; IOB3, IgG, and 4A1, IgG2 (Misotest ELISA kit,
Commonwealth Serum Laboratories, Melbourne, Australia).
The reactivity of mucins with the three new MAb was not
reduced by digestion with neuraminidase (1.Omgml-' incu-
bated at 370 for up to 16h), wherease reactivity with the
anti-SIMA MAb 4D3 was abolished.INTESTINAL MUCINS IN COLORECTAL CANCER 801
Immunohistochemical reactivity ofMAbs: cellular and
subcellular distribution
(i) Normalgastrointestinal tract The reactivities of the MAb
2C3, 9B5, 1OB3, 4A1, and 4D3 in formalin-fixed sections of
the normal G-I tract are summarised in Table I. None of the
five MAb reacted with gastric mucin.
The anti-LIMA MAb 2C3 reacted specifically with mucin
in the large intestine, with diffuse, strong reactivity with
goblet cells and secreted mucin throughout the large intes-
tine. Apical membrane-associated reactivity on the surface,
and at the base of the crypt was also observed. At the light
microscopic level, it was not possible to discern whether this
apical pattern represented definite membrane-associated or
intracellular reactivity. MAb 2C3 did not react with mucin in
the small intestine, with the exception of restricted reactivity
in the terminal ileum. A very similar pattern oflarge intestine
reactivity was observed with MAb 9B5 which reacted more
strongly with goblet cells in the upper crypt (Figure la), but
in contrast to MAb 2C3, MAb 9B5 showed restricted or
trace reactivity with goblet cells in the proximal small intes-
tine (Table I). MAb IOB3 reacted with goblet cell and
secreted mucin diffusely throughout the large intestine and
more strongly with cells in the lower crypt (Figure lb); but,
unlike 2C3 or 9B5, IOB3 reacted with mucin throughout the
small intestine.
In contrast the three MAb above, the anti-SIMA MAb
4D3 and 4A1 reacted with small intestinal mucin, but not
with large intestinal mucin. MAb 4D3 reacted with goblet
cell and secreted mucin, diffusely and intensely, throughout
the small intestine, whereas MAb 4A1 showed patchy to
restricted reactivity with goblet cell mucin in the small intes-
tine. In contrast to MAb 4D3, MAb 4A1 showed apical
membrane-associated reactivity with cells in the upper crypt
and luminal surface in the colon (Figure lc).
Notably, there was no observable difference in the intensity
or distribution of MAb reactivities between biopsy and
autopsy specimens, consistent with previous evidence that
mucin antigens were relatively resistant to physicochemical or
enzyme degradation. These results validate the use ofautopsy
samples for studies of mucin antigen distribution in the GI
tract.
In contrast to the anti-mucin MAb described above, reac-
tivity with the anti-CEA polyclonal antiserum was virtually
absent throughout the normal gastrointestinal tract apart
from occasional apical membrane-associated reactivity at the
luminal surface of the large intestine. No reactivity with
goblet cells or secreted mucin was observed.
(ii) Colorectal carcinoma Sections of 100 cases of colorectal
cancers were stained by immunohistochemistry and assessed
histologically for reactivity with different tissue and subcel-
lular compartments (Table I). Each of the five antibodies
reacted, with variable intensity, with secreted mucin in glan-
dular lumina and so-called 'mucinous lakes' (Figure 2a).
Additional individual patterns were consistently observed
Table I Immunohistochemical reactivity of MAbs in normal
gastrointestinal tract and colorectal cancers
Reactivity with MAb
Tissue 2C3 9B5 1OB3 4A1 4D3
Normal stomach -
Normal small intestine
Goblet cell mucin - + + + + + + + +
Extracellular mucin - + + ++ - + + +
Apical membrane -
Normal colorectum
Goblet cell mucin +++ +++ +++
Extracellular mucin +++ +++ + + +
Apical membrane + + - +
Colorectal cancer
Gobletcellmucin + + +++ +++ +++
Extracellular mucin +++ +++ ++ +++ +++
Apical staining +++ +++ - + + +
Golgi staining - + - +
Figure 1 Immunoperoxidase staining of a section of morpho-
logically normal colon using two of the new MAb (original
magnification x 25): a, MAb 9B5 showing reactivity with goblet
cell mucin (arrow) and in the apical membrane (arrowhead); b,
MAb 10B3, showing reactivity with goblet cell mucin (arrow),
and c, MAb 4A1, showing reactivity with the apical membrane
(arrowhead).
with each MAb. Notably, various combinations of MAb
exhibited mosaicism within the cancer, i.e. particular areas of
a given cancer showed complementary reactivities with
different MAb.
MAb 2C3 and 9B5, which react with normal large intes-
tinal mucin, reacted only rarely with goblet cells when pres-
ent in well differentiated cancers. Both MAb reacted with a
rim of reactivity associated with the apical membrane of
carcinoma cells, more strongly than that observed in normal
colon (Figure 2b), and occasionally reacted with the sup-
ranuclear golgi zone (Figure 2c). MAb IOB3, reactive with
normal large and small intestine mucin, reacted strongly with
goblet cells when present (Figure 2d). This pattern was differ-
ent from that of MAb 2C3 and 9B5, but similar to that
observed for the two anti-SIMA MAb (see below). MAb
1OB3 also reacted weakly with carcinoma cell cytoplasm and
occasionally with the apical region.
In contrast to the anti-LIMA MAb, the anti-SIMA MAb
4D3 and 4A1 reacted strongly with goblet cell mucin in
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Figure 2 Immunoperoxidase staining of specimens ofadenocarcinoma of the colon, using anti-mucin MAb and showing reactivity
with different subcellular and tissue compartments: a, reactivity with a mucinous lake (arrow) using anti-SIMA MAb 4D3 (original
mag x 25); b, reactivity with the apical rim of glands using MAb 9B5 (original mag x 25); c, reactivity with the supranuclear
'Golgi zone' using MAb 9B5 (original mag x 50), and d, reactivity with goblet cell mucin using MAb 10B3 (original mag x 25).INTESTINAL MUCINS IN COLORECTAL CANCER 803
colorectal cancer. In addition, MAb 4D3 occasionally reacted
with the apical region, whereas MAb 4A1 reacted strongly
with the apical region of cells and occasionally with the
supranuclear golgi zone. Polyclonal anti-CEA antiserum
showed strong reactivity with intraluminal material and with
the apical membrane, weaker reactivity with the cytoplasm,
but no goblet cell reactivity (Figure 3).
In terms of subcellular reactivities of each MAb, the
general trends were thus as follows: intraluminal secreted
mucin reacted with each MAb and anti-CEA; goblet cells,
when present within the cancer, reacted strongly with either
MAb 4D3, 4A1 or IOB3; the apical membrane region reacted
with MAb 2C3, 4A1, and 9B5 and anti-CEA; the sup-
ranuclear golgi zone reacted mainly with MAb 4A1. Thus,
the biosynthetic pathways of goblet-type cancer cells ap-
peared to have undergone an alteration from the normal
large intestinal pattern, such that two inappropriate mucin
epitopes were detected by MAb 4D3 and 4A1. However, the
less differentiated cancer cells contained both of the 2C3- and
9B5-reactive normal colonic mucin epitopes in addition to
the atypical 4D3- and 4AI-reactive small intestinal mucin
epitopes.
(iii) Perineoplastic mucosa In the sections of 99/100 colorec-
tal carcinomas that were examined, there was a limited
amount of non-neoplastic mucosa present. Staining patterns
were thus determined for the narrow Transitional Mucosa I
(TM-I) zone, the broader Transitional Mucosa II (TM-II)
zone, and in morphologically normal mucosa beyond these
two zones, which was present in 49 of the 100 cases.
The reactivity patterns of MAb 2C3, 9B5 and IOB3 in
morphologically normal mucosa beyond the TM zones were
essentially indistinguishable from their patterns in colorectal
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mucosa from normal subjects (Figure 4a). In the TM-I and
TM-II zones, as might be anticipated, the goblet cells reacted
normally with the anti-LIMA MAb 2C3 and 9B5 but, in
addition, there was strong reactivity with columnar cells in
the apical and supranuclear golgi regions.
Notably, anti-SIMA MAb 4A1 and 4D3, which do not
react with normal colorectal mucin, reacted not only with
TM-I and TM-II, but also with the morphologically normal
mucosa beyond these zones. In morphologically normal mu-
cosa, MAb 4D3 showed predominantly goblet cell and extra-
cellular mucin reactivity, as observed in the normal small
intestine and colorectal cancer. MAb 4A1, similarly to its
pattern in the cancer, showed strong apical membrane-assoc-
iated reactivity and goblet cell reactivity, and in contrast to
its pattern in the cancer, strong golgi reactivity (Figure 4b).
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Figure 3 Immunoperoxidase staining of a moderately well-
differentiated adenocarcinoma of the colon using polyclonal anti-
CEA antiserum, showing reactivity with extracellular material in
the lumen (arrow) and the carcinoma cell cytoplasm (arrowhead)
(original mag x 50).
Figure 4 Immunoperoxidase staining of the perineoplastic TM-I
zone using: a, MAb 10B3, which shows strong reactivity with
goblet cell (arrowhead) and secreted mucin (arrow) (original mag
x 25); b, MAb 4A1, which shows strong Golgi (arrow) and
apical reactivity (arrowhead) (original mag x 25).
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CEA, where present in the perineoplastic
apical, but not goblet cell reactivity. The
that, outside the cancer, the morphological
tal goblet cells are capable of expressing a
phenotype.
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markedly weaker than in the cancers, and weaker in intensity
and less frequent than for the mucins (TM-I, 65% TM-II,
36% and morphologically normal, 24%) (Figure 5).
Taken together, 4A1 and 4D3 reacted with 95% of the
cancer cases including six of the eight cases that were
negative for CEA. In the TM-I zone, 94% reacted with either
4D3 or 4A1, and 88% of cases in the TM-II zone. In the
morphologically normal mucosa beyond the TM, 80% reac-
ted with either 4D3 or 4A1 (Figure 5). Of interest was the
observation that there were some cases in which the mucin in
the transitional mucosa reacted with MAb 4D3 or 4A1,
whilst the mucin in the cancer did not.
Correlation ofsemiquantitative immunohistochemical mucin
antigen reactivities with clinicopathologicalparameters
iummation of the Further analysis of the semiquantitative immunohistochem-
ical reactivities of cancers was undertaken to determine any
I colorectal mucin correlation with various clinicopathological parameters: age,
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:h MAb IOB3. The invasiveness, extent of fibrosis and lymphocyte response. The
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nt mucosa (Figure An important finding from this analysis was that the anti-
SIMA MAb 4D3 and 4A1 reacted with a high percentage of
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reactive even for poorly-differentiated carcinoma, 81% with
2C3, 74% with 9B5, and 81% with 4A1, whereas fewer were
reactive with IOB3 (49%) and 4D3 (56%).
Adjacent There was no strict correlation of the reactivities of each Adjacent MAb with any parameter examined (every MAb reacted with
>50% of cancers in each subcategory). However, some
* 2C3 trends did emerge from this analysis (Table II). MAb 4D3
reacted with mucinous and tubular carcinomas at a higher
frequency (89 and 82%, respectively) than papillary car-
cinomas (56%); whereas anti-CEA antisera reacted with
9B5 fewer mucinous carcinomas (79%) than papillary or tubular
carcinomas (100 and 97%, respectively). MAb 4A1 showed a
higher frequency of reactivity with expanding (91% positive)
10B3 versus infiltrating carcinomas (73% positive). MAb IOB3 and 4D3 reacted with fewer carcinomas with a marked lym-
phocyte response (70 and 61%, respectively, c.f., 91% posi-
tive for each MAb in carcinoma with little lymphocytic
4A1 response).
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Figure 5 Semiquantitative immunohistochemical reactivities of
each of the five anti-mucin MAbs and the anti-CEA antiserum in
100 colorectal cancers and perineoplastic mucosa. Number of
cases plotted against immunohistochemical staining score (see
text). The different shading indicates negative (0), weak, moderate
and strong (black) staining.
Quantitation by ELISA ofmucin antigens
Sandwich ELISA were developed for the quantitation of
mucins reactive with each of the MAb 2C3, 9B5, IOB3, 4A1
and 4D3 in the normal gastrointestinal tract and in cancers.
An example of a standard curve for the one of the MAb,
4A1, with cancer mucin preparation no. 3266, is shown in
Figure 6. This ELISA and similar ones using the other MAb
could reliably detect 2-250 antibody-reactive units per ml.
These assays were not affected by concentrations of guani-
dinium HCI<0.4 M and could therefore be used to assay
tissue homogenates prepared in 4 M guanidinium HCI then
diluted 1:10. Results of sandwich ELISA of tissue extracts
from segments of the normal large intestine and from six
specimens of colorectal cancer are shown in Figure 7. Mucins
were subsequently purified from these tissue extracts by
cesium chloride (CsCI) gradients, the yield of mucin anti-
genicity was 80 to 100%, thus accounting for virtually all of
the tissue antigenicity.
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Table II Correlation ofmucin antigen detection with clinicopathological features ofcolorectal
carcinoma
Clinico- No.
pathological of Percentage ofcases positivefor Ab reactivity
Feature cases 2C3 9B5 1OB3 4A1 4D3 CEA
Stage
A 13 100 92 77 77 85 92
B 24 100 96 92 92 88 92
C 37 92 95 81 92 73 89
D 7 86 100 100 100 71 100
Tumour size
0- 10cm3 33 94 97 85 88 88 94
11-30cm3 31 97 90 87 90 77 90
30-150cm3 11 91 91 81 100 72 100
Histological type
Mucinous 19 95 95 89 100 89 79
Papillary 9 89 100 78 78 56 100
Tubular 62 95 90 85 92 82 97
Differentiationa
Well 43 88 83 86 79 74 79
Mod-well 10 70 80 70 50 60 80
Mod 88 92 86 70 79 72 80
Mod-poor 12 92 92 83 92 92 67
Poor 43 81 74 49 81 56 67
Invasiveness
Infiltrating 26 96 100 88 73 85 96
Expanding 57 95 93 84 91 82 91
Lymphocyte response
Little 11 91 91 91 100 91 82
Moderate 41 93 95 90 90 98 93
Marked 23 100 96 70 96 61 96
Fibrosis
Little 26 96 88 85 92 69 88
Moderate 36 97 97 83 91 89 94
Extensive 23 91 96 91 100 83 96
Site
Rt. colon 18 100 94 89 100 78 89
Lt. colon 18 100 100 78 89 72 83
Rectum 39 92 87 85 90 77 97
Total 100 95 90 85 91 77 92
aThe differentiation sometimes varied from one part of a cancer to another, so for this parameter,
correlation with mucin antigen reactivity was determined for each sample. Several samples were available
from about half of the cases.
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Figure 6 Sandwich ELISA standard curve for anti-SIMA MAb
4A1 using cancer mucin preparation 3266.
(i) Normal large intestine The anti-LIMA MAb 2C3 and
9B5, as well as MAb IOB3, reacted strongly with mucin in all
five segments of the large intestine from the ascending colon
to the rectum; whereas the only trace or undetectable reac-
tivity was evident using the anti-SIMA MAb 4A1 and 4D3
(Figure 7). Thus, for 2C3, the levels ranged from 6,000 to
approximately 30,000 2C3-reactive units/g wet weight of tis-
sue, with the highest levels generally found in the sigmoid
colon and rectum (left side). As expected, 2C3-reactive
LIMA was undetectable in extracts of normal duodenum,
jejunum and ileum, <10 units g-' tissue (data not shown).
Mucin reactive with MAb 9B5 was detected at levels usually
about 1,000 to 4,000 9B5-reactive units/g tissue (Figure 7),
but only trace amounts were detected in the small intestine
(data not shown). Mucin reactive with MAb IOB3 was also
detected at levels ranging from 1,000 to 3,000 units/g' tis-
sue, and in this case, similar levels were also detected in the
small intestine (data not shown).
In contrast to this, the anti-SIMA MAb 4A1 showed only
traces of reactivity in the large intestine, ranging from 10 to
50 4Al-reactive units g' tissue. The other anti-SIMA MAb
4D3 did not react with large intestinal mucin, i.e., < 10
4D3-reactive unitsg'I tissue, compared with its strong reac-
tivity with small intestinal mucin, 50,000 to 100,000 units g'
tissue (data not shown).
(ii) Colorectal cancer specimens In extracts of colorectal
cancers, ELISA detected quantitative increases or decreases
in the expression of MAb 2C3, 9B5 and 1OB3-reactive
mucins, which are normally detected in that organ, as well as
the inappropriate expression of anti-SIMA 4D3 or 4A1-
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Figure 7 Quantitation by sandwich ELISA, using each of the
five MAbs of mucin antigens from extracts of five segments of
the normal large intestine and from six specimens of colorectal
cancer. Different shading patterns are used to highlight different
cancer specimens.
reactive mucins, not normally detected at significant levels in
that organ (Figure 7). This analysis also demonstrated the
heterogeneity of mucins in colorectal cancers. For example,
cancer specimens 1, 2 and 4 show strong reactivity with all
five MAb, mucin from specimen 3 reacts with 2C3, IOB3 and
4D3, specimen five with only IOB3 and 4D3, and specimen 6
with only 4D3 and 4A1.
Levels of 2C3-reactive mucin in colorectal cancer extracts,
compared with levels in the normal colon extracts, were
increased in two cases (25,000 and 250,000 units -1), de-
creased in two cases (400 and 3,000 units g-1), and not
detected in two cases. Levels of 9B5-reactive mucin were
elevated in one sample (20,000 units g-'), within the normal
range in two samples (3,300 and 3,9000 units g- ), and not
detected in three samples. The levels of 1OB3-reactive mucin
in the cancer samples were elevated in five to six cases,
ranging from 11,000 to 400,000 units g-1, and not detected in
one case. Elevated levels of4D3-reactive mucin were detected
in all six cancer samples, ranging from 1,500 to 33,000
units g'. The levels of 4AI-reactive mucin in the cancer
samples were elevated in four to six cases at 600 to 20,000
units g-', and not detected in two cases.
Discussion
A new panel of MAb reactive with intestinal mucins was
used to investigate the distribution and heterogeneity of
antigen expression in 100 cases of colorectal carcinoma. The
results were correlated with clinicopathological indices and
compared with the distribution of a well characterised colo-
rectal tumour antigen, CEA. The panel ofMAb included two
MAb, 4D3 and 4A1, that react with epitopes on SIMA,
which is an oncofoetal antigen of the colon, but is not
detectable in the normal adult colon (Hertzog et al., 1991).
The panel also included two MAb, 2C3 and 9B5, that recog-
nised mucin normally localised predominantly in the normal
large intestine and one MAb, IOB3, that reacted with epi-
topes on SIMA and LIMA.
From the combined data from immunohistochemistry of
tissue sections and ELISA of mucins extracted from normal
and cancer tissues, general conclusions can be made concern-
ing the specificity of these MAb:
- Each MAb recognises a different epitope.
- In each case the epitope is present more than once on the
antigen.
- Antigens extracted from normal and cancer tissues have
buoyant densities characteristic for mucin glycoproteins.
- With the exception of the anti-SIMA MAb 4D3, the MAb
recognise neuraminidase-insensitive epitopes.
- None of the MAb react with gastric mucin which distin-
guishes them from another series of gastrointestinal mucin
antibodies (Bara et al., 1984).
- The patterns of reactivity of these MAb, particularly in
the normal gastrointestinal tract are different from that
described for MAb to A, B, H and Lewis-type blood
groups (Wolf et al., 1989; Abe et al., 1986; Itzkowitz et
al., 1986; Kim et al., 1986; Sakomoto et al., 1986; Schoen-
tag et al., 1987).
- The reactivity of the mucin antigens is resistant to for-
malin fixation and paraffin embedding of the tissues.
- The two anti-SIMA MAb recognise cancer mucin antigens
that are abnormal for the colorectum.
As previously discussed, the sensitivity ofthe 2C3 and 4D3
epitopes to P-elimination, periodate oxidation or neuramini-
dase (for 4D3 only) suggest that these epitopes contain, or
are influenced by carbohydrate moieties (Hertzog et al.,
1991). Further biochemical characterization of the epitopes
for all of these MAbs is in progress, but is limited by the
availability of native antigen in sufficient quantities. The
reactivity of 9B5 or 4A1 with the Golgi zone is suggestive of
possibly a peptide or core carbohydrate epitope; preliminary
data suggest 4A1 reactivity is periodate sensitive (data un-
published) consistent with a carbohydrate-dependent epitope.
Since the genes coding for two intestinal core proteins desig-
nated MUC2 and MUC3 have been cloned, (Gum et al.,
1989; 1990) it would be interesting to correlate these with
SIMA and LIMA, and determine whether atypical SIMA
expression in colorectal cancers is the result of altered glyco-
sylation of normal core protein(s), or expression of new core
protein(s).
Atypical reactivity of the anti-SIMA MAbs 4D3 and 4A1
in colorectal carcinomas was usually observed with tissue
components associated with mucin, namely glandular lumen
secretions, mucinous lakes and goblet cells. Thus, even the
well differentiated goblet cells, when present in colorectal
cancer, produce the abnormal antigen SIMA. In addition,
undifferentiated carcinoma cells also contained material reac-
tive with the two anti SIMA MAb, particularly 4A1, in
which case staining was observed in the region of the apical
membrane. The MAb IOB3, while reactive with both SIMA
and LIMA in normal adults, showed a pattern of cellular
reactivity in colorectal cancers that was similar to the anti-
SIMA MAb, again highlighting the breakdown of normal
mucin antigen patterns that occurs in colorectal cancer.
Abnormal SIMA expression was detected in a high pro-
portion of colorectal carcinomas, even those at an early stage
of development such as those at stages A and B (89%
positive for 4D3, 86% positive for 4A1) and those of small
size (<10cm3, 88% positive for 4D3 and 4A1). Thus aber-
rant SIMA expression may be an early event in colon carcin-
ogenesis and is even present in the potentially premalignant
perineoplastic mucosa (see below). The utility of the two
anti-SIMA MAb and anti-CEA, all of which react with
antigens not normally present in the colon, in the detection
of neoplastic change in the colon and rectum, was further
enhanced by the findings that these antibodies reacted with a
high proportion of cancers, regardless of histological type,
differentiation, stage, site, size, age, or sex.
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mucin antigen reactivity with any single clinicopathological
index, some trends did emerge. The anti-SIMA MAb 4D3
showed a tendency for stronger staining associated with a
less malignant phenotype, namely carcinoma of stage A/B,
smaller size, better differentiation. Both 4D3 and 10B3 posi-
tive tumours had a lower lymphocyte infiltrate, a feature
previously reported for histologically-defined 'mucinous tu-
mours' (Pihl, 1984) and interpreted as an indication that
mucins may 'shield' cancers from the host immune response
(Greaves et al., 1980).
Over 90% of colorectal cancers contained mucin reactive
with the two anti-LIMA MAb 2C3 and 9B5 in extracellular
mucinous lakes or glandular lumen secretions as observed
with the anti-SIMA MAb. However, in contrast to the cel-
lular pattern of anti-SIMA reactivity, the two anti-LIMA
MAb did not react with goblet cells in colorectal cancers
(albeit the site of reactivity in the normal colon), but reacted
with undifferentiated carcinoma cells, in the apical membrane
region, and less frequently in the Golgi zone. Some
undifferentiated carcinoma cells of the majority of colorectal
cancers appear, therefore, to be capable of synthesising and
secreting normal colonic mucin. Thus, the normal colonic
mucin, LIMA is produced in colorectal cancers by atypical
cells, possibly goblet cell precursors or intermediate cells
(Dawson & Filipe, 1976) but not by goblet cells. In addition
to this qualitative abnormality of LIMA production in col-
orectal cancers, quantitative differences from normal were
detected, by ELISA using MAb 2C3 or 9B5, as increased
production in some cases and absence in others. The occur-
rence of LIMA in the cancers showed no trends with any
clinicopathological parameters; the anti-LIMA MAb and the
anti-SIMA MAb even reacted with a high proportion of
colorectal cancers that would have been diagnosed histo-
logically as 'non-mucinous'. These observations may be ex-
plained by the reactivity of these MAb frequently with mucin
antigens in cellular or tissue compartments not normally
associated with mucins.
The atypical subcellular and extracellular distribution of
reactivity with these anti-mucin MAb is a reflection ofaltered
glycoprotein biosynthesis and warrants further investigation
at the ultrastructural and biochemical level. Altered meta-
bolism may take the form of incomplete synthesis, degra-
dation or synthesis of new (neo-) molecules as proposed for
other differentiation-associated glycoconjugates (Hakomori &
Kannagi, 1983). However, mucins differ from other tumour
marker antigens, such as those on the cell surface, because
they are more extensively glycosylated and are naturally
secreted molecules. Mucin production by tumours may there-
fore be more readily detected in biological fluids, and may
have different consequences for tumour progression. Abnor-
mal mucin production may influence the progression of the
tumour by affecting processes such as growth or invasion, or
by presenting 'unseen' antigens to the host immune system.
Furthermore, abnormal mucin glycoprotein metabolism or
distribution may be an important factor in determining
whether these antigens reach the blood, as proposed for CEA
(Hamada et al., 1985). Indeed, each of these MAb, on
occasions, was observed to stain serum in blood vessels in
specimens of colorectal cancer, and preliminary studies using
ELISA have also detected mucin antigens in blood samples
from some patients with colorectal cancer.
Whatever the underlying cause of the altered mucin glyco-
protein metabolism in colorectal cancers, it is interesting that
it varies in detail from one cancer to the next. Thus, cancers
showed different profiles of reactivity with the individual
anti-mucin MAb and CEA, evident in both immunohis-
tochemical and ELISA studies. The reactivity of different
regions of a cancer specimen were also frequently comple-
mentary in nature. Similar 'mosaicism' of reactivity in can-
cers has been described for another series of related tumour
antigens (Nakasaki et al., 1989). A cocktail of complemen-
tary antibodies would therefore react with a higher propor-
tion of cancers and with more cells in a tumour than any of
these individual antibodies, and may be the optimal reagent
to use for tissue or blood diagnosis, immunolocalisation or
tumours, or delivery of immunotoxins.
In the perineoplastic mucosa, the frequency of reactivity
with the anti-SIMA MAbs 4D3 and 4A1 decreased only
slightly from TM-I to TM-II (70 and 90% to 62 and 86%
respectively), compared with the dramatic drop in frequency
and intensity ofreactivity with CEA (65% in TM-I, and 35%
in TM-II). Similarly, abnormal mucin antigen expression
detected by one of the anti-SIMA MAbs 4D3 or 4A1 was
detected in the morphologically normal mucosa in a high
proportion of cases (80%) versus CEA (24%). Clearly, these
apparently normal cells are undergoing biochemical change.
It remains an open question as to whether this change is
precancerous (Filipe, 1969; Decaens et al., 1983) or reactive
(Isaacson & Attwood, 1979; Boland & Kim, 1987). Future
studies will be directed to the factors that may be responsible
for such changes, and the extent of these or similar changes
in mucosa distant from the tumour.
In conclusion, we have described alterations of mucin pro-
duction in the majority of colorectal cancers of every stage,
differentiation and histological type, size and site. Not only
were the new, atypical mucins (SIMA) produced, but the
normal colonic mucin (LIMA) was found in abnormal cell
types, subcellular and tissue compartments. The broad reac-
tivity of this panel of MAb would be an advantage for their
use, perhaps in combination with each other and/or CEA, in
immunolocalisation, serological monitoring, or therapy of
colorectal cancer.
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